
    
      The original study protocol has been amended due to requests from the Food and Drug
      Administration (FDA), requests from the funder of the study, Bill & Melinda Gates Foundation
      (BMGF), to add an additional interim analysis for immunogenicity data that will accelerate
      the release of key results to help the planning of other studies, and to further align the
      protocol to other GSK studies and to the challenge model established at the Cincinnati
      Children's Hospital Medical Centre.
    
  